Introduction
Nasopharyngeal carcinoma (NPC) is the most common head and neck malignancy, which is endemic in Southeast Asia. 1 Over 60,600 new cases were diagnosed and almost 34,100 patients were dead in China in 2015. 2 Also, 60%-70% of patients are diagnosed with locoregionally advanced nasopharyngeal carcinoma (LANPC). 3, 4 Based on the anatomical location and radiosensitivity, radiotherapy (RT) is the primary therapeutic regimen for NPC. With RT alone, the 5-year overall survival (OS) rate for stage I is >90%. However, the 5-year OS rate is only 67%-77% in LANPC treated with RT alone. 5 In the era of two-dimensional RT (2D-RT), several studies have shown that the addition of concurrent chemotherapy to radiation improves local control and OS. [6] [7] [8] [9] Thus, concurrent chemoradiotherapy (CCRT) is the standard therapeutic model recommended by the National Comprehensive Cancer Network guideline.
Intensity-modulated radiotherapy (IMRT) has brought a great progress in the treatment of LANPC. It provides better tumor target coverage with lower
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He et al radiation-associated toxicities than 2D-RT, and thus, the locoregional control has been substantially improved. 10, 11 Meanwhile, as reported, IMRT alone can achieve the same or similar treatment effect and significantly decrease the adverse reactions in patients with LANPC, compared with the 2D-RT combined with chemotherapy. The 3-year OS rate was 80.43% for IMRT alone and 74% for 2D-RT combined with chemotherapy. 12 Furthermore, Sun et al reported that by the addition of concurrent chemotherapy to IMRT, no survival benefits were observed in the 5-year disease-specific survival, local recurrence-free survival, regional recurrencefree survival, and distant metastasis-free survival in 603 NPC patients with stage III-IVb. 13 What is more, more treatmentassociated toxicities were observed in CCRT group than in IMRT alone group. Similarly, Lin et al found that compared with IMRT alone, CCRT provided no obvious clinical benefit and induced significantly higher grade 3-4 acute toxicities in 370 LANPC patients. 14 On the contrary, Xie et al reported that the addition of concurrent chemotherapy increased the estimated 5-year OS rate from 73.7% (without concurrent chemotherapy) to 81.8% (with concurrent chemotherapy), but was accompanied with increased toxicities. 15 Thus, it is controversial whether the addition of concurrent chemotherapy brings more clinical benefits for LANPC in the era of IMRT.
In this study, we conducted a meta-analysis using available evidence from randomized controlled trials to compare the efficacy and toxicity of CCRT to RT alone for LANPC in the era of IMRT.
Materials and methods
Search strategy and selection criteria
PubMed, Embase, Cochrane Library, China National Knowledge Infrastructure, Wanfang Database, Weipu Information Resources System, and Chinese Biomedical Database were searched up to August 2017. References of relevant articles were also searched carefully.
Literatures were screened for eligibility using the following criteria: 1) participating patients with non-metastatic NPC diagnosed as stage III-IVb, 2) studies comparing IMRT combined with current chemotherapy with IMRT alone, and 3) randomized controlled trials.
Reports were excluded by the following criteria: 1) republication of literature; 2) treatment included 2D-RT; 3) no randomized controlled trials or any reviews, comments, and letters; 4) concurrent targeted therapy; 5) induction chemotherapy or adjuvant chemotherapy was applied; and 6) full text was unpublished. Eligibility assessment was performed by two reviewers. Disagreements between reviewers were settled by discussion.
Data extraction
Extraction was performed by two reviewers. Disagreements were resolved by discussion. We contacted the original study researchers for indistinct data and removed the data from stage II NPC patients. The following information was extracted: first author, publication year, patient number, inclusion period, random method, treatment regimen, and outcomes. The efficient outcomes were overall response rate (ORR), complete response rate (CRR), and OS. As for the toxic outcomes, data on grade 3-4 adverse events of hematologic toxicity, gastrointestinal reaction, radiation-induced oral mucositis, and radiodermatitis were extracted. If the study reported relevant adverse events separately, for example, nausea, vomiting, and diarrhea, the higher event rate was used to approximate the overall events. Among the 15 studies, 1 study utilized Common Terminology Criteria for Adverse Events criteria 3.0 for adverse events, and the rest utilized the World Health Organization criteria. However, the evaluation standard is very similar in these two criteria for adverse events. Thus, these data could be combined in this meta-analysis.
Assessment of risk of bias and data analysis
We assessed the risk of bias referring to the guidance of Cochrane Handbook for Systematic Reviews of Interventions (5.1.0). 16 Statistical analysis was performed by Review Manager Software (RevMan 5.3; Cochrane Collaboration, Oxford, UK).
ORR, CRR, OS, and grade 3-4 advent events were analyzed quantitatively by using the risk ratio (RR), and 95% CI was calculated. RR represents the risk ratio of an event which occurred in the CCRT group versus the RT group. An observed RR <1 and a 95% CI which did not overlap 1 with P<0.05 indicated that CCRT could offer more benefits to patients with LANPC and would be considered statistically significant. Heterogeneity was used to evaluate the variability in studies by I 2 statistic. If I 2 statistic was <50%, we considered the heterogeneity was acceptable, and we used the fixedeffects model for the meta-analysis. The value of I 2 ≥50% was considered to indicate substantial statistical heterogeneity. The causes of heterogeneity among the results of studies were explored. Then, a random-effects model was used. 
Results
Search results and characteristics of studies
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CCRT versus RT in LANPC in the era of IMRT Infrastructure, Wanfang Database, Weipu Information Resources System and Chinese Biomedical Database (shown in Supplementary materials). Furthermore, possibly useful publications were hand-searched, but eligible studies were not found. One thousand three hundred and twenty citations remained after removing duplicates. After reviewing the titles and abstracts carefully, 1292 citations did not match the inclusion criteria. Finally, 28 citations remained. After reading these 28 studies carefully, 13 studies were removed. These were removed because of the following reasons: three citations were not truly randomized; in three citations, the concurrent drugs were molecular targeted therapy; one citation was a conference abstract; in three citations, adjuvant chemotherapy was administered; and in the remaining three citations, not all patients were treated with IMRT. Collectively, 15 clinical studies were available for this meta-analysis ( Figure 1 ).
17-31
The characteristics of the 15 studies are summarized in Table 1 . We included 1142 patients in the meta-analysis, of whom 573 received CCRT and 569 were allocated to IMRT alone group. Baseline characteristics were balanced in all studies. All patients included in this meta-analysis were LANPC (stage III-IVb). The concurrent chemotherapy drugs reported in these studies included cisplatin, nedaplatin, docetaxel, 5-fluorouracil, xeloda and s-1 (tegafur, gimeracil and oteracil potassium). ORR data were available in 12 studies, CRR data in 13 studies, and OS data in 6 studies. Almost all studies assessed the response rate according to Response Evaluation Criteria in Solid Tumors at 3 months after RT by magnetic resonance imaging.
Risk of bias of eligible studies
Among the selected 15 studies, 9 studies were assessed as low risk of bias because these trials were assigned by the random number table. Two studies were evaluated as high risk because these two trials were assigned by the day on which a patient is admitted to the hospital. It was unclear how to generate random sequence in four studies. Allocation concealment was not clearly reported in all studies. Blinding of participants was not applied in all 15 trials because of intervention measures. Blinding of outcome assessment was not reported in 13 trials and was reported in the remaining 2 trials. Fourteen studies reported complete outcome data. One study reported lost to follow-up, but we assessed this study as low risk because the number of lost to follow-up was balanced in both groups of this study (Liu et al, 20 the number of lost to follow-up in CCRT: 3, RT: 4; Figure 2 ). The publication bias might exist according to the funnel plots ( Figure S1 ). Chen et al, 17 2017
Li et al, 18 2010
Liu et al, 20 2012
Liu et al, 21 2015
Tian and You-Ming, 22 He et al showed that the addition of concurrent chemotherapy contributed to a significant decrease in distant metastasis rate, compared with IMRT alone. 21, 25, 29 In CCRT group, higher grade 3-4 adverse reaction was observed in hematologic toxicity (RR 2. 25 studies=8; I 2 =86%) was not significantly different between these two groups. We observed that grade 3-4 gastrointestinal reaction had obvious heterogeneity. Subgroup analyses were conducted ( Figure S2) , and results showed that heterogeneity was obviously decreased in the subgroup using different chemotherapy regimens. Cisplatin-based concurrent chemotherapy indicated higher grade 3-4 gastrointestinal reaction in CCRT group than in RT group, while no obvious increase of grade 3-4 gastrointestinal reaction was found in nedaplatin-based studies.
We performed a sensitivity analysis by excluding each study once in all of the genetic models. No obvious influence on final results, including ORR, CRR, OS and grade 
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Discussion
NPC has an uneven worldwide distribution and a high incidence rate is found in Southeast Asia. 1 RT is the main treatment for NPC. However, the 5-year OS rate for LANPC is only 67%-77% by utilizing 2D-RT. 3 With the development of RT technology, IMRT is recommended to treat NPC because it brings better tumor target coverage and less radiation-associated toxicities. 6, 7, 32 In the era of IMRT, it is unclear whether adding concurrent chemotherapy provides additional benefits for LANPC.
In this meta-analysis, all included studies were prospective randomized controlled studies. The analysis results pooling 15 clinical studies indicated that concurrent chemotherapy plus IMRT contributed to better prognosis than IMRT alone. CCRT significantly improved ORR, CRR, and 
3-year OS B
5-year OS C
OS. As for the treatment-associated toxicities, CCRT led to more tolerated adverse events compared with IMRT alone.
Previous published meta-analyses showed that the addition of concurrent chemotherapy improved prognosis in LANPC patients in the era of 2D-RT. For example, it was reported that the 5-year OS was significantly improved after the addition of concurrent chemotherapy in a meta-analysis from 16 trials involving 2576 patients with LANPC, when compared with RT alone. 33 Furthermore, a meta-analysis, pooling the data of NPC in endemic areas, showed that CCRT group also improved the 5-year OS, compared with RT alone. 34 In terms of toxicities, the addition of concurrent chemotherapy is associated with higher incidences of acute and late toxicities. It was shown that cisplatin-based chemotherapy combined with RT increased the risk of treatmentrelated death and acute toxicities, and the overall incidence rates of treatment-related mortality in CCRT and RT alone were 1.7% and 0.8%, respectively. 35 Moreover, the overall 
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CCRT versus RT in LANPC in the era of IMRT incidence of late toxicities was 30.7% in CCRT group, while it was 21.7% in RT alone group. 36 In these meta-analyses, the radiation mainly utilized 2D-RT methods, and a very small group of patients were treated with IMRT. These data are consistent with our conclusions that concurrent chemotherapy improves OS in LANPC, compared with IMRT alone.
To our knowledge, this is the first meta-analysis focusing on comparing the efficacy and toxicity of CCRT to IMRT alone for LANPC. This meta-analysis has several limitations. First, randomization method and allocation concealment were not reported in all included studies. Second, the recruited patient population was small in these included studies. Third, the median follow-up time is not long enough in some trials. Thus, we need multicenter randomized controlled trials and long-term follow-up to evaluate the eventual efficacy and toxicity of concurrent chemotherapy plus IMRT.
In conclusion, in the era of IMRT, current evidences show that compared with RT alone, CCRT still brings clinical benefit in LANPC with acceptable toxicities.
